A
ATRC
Atricure
27.30
+0.39+1.43%Closed17:29 06/09 EDT
OPEN/PREV CLOSE26.96/26.92
TODAY RANGE26.84-27.63
VOL607.25K
MARKET CAP1.38B
52 WEEK RANGE25.36-43.18
AVG VOL (3M)757.21K
% TURNOVER1.20%
TURNOVER0
P/E (TTM)-282.9016
% RANGE2.95%
EPS(TTM)-0.0965
P/E(FORWARD)1,365.00
P/B2.811
BVPS9.71
DIVIDEND--
P/S2.543
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.33B
SHARES OUTSTANDING50.64M
NEXT EARNINGS07/27-07/31
FREE FLOAT48.55M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Barron‘s·05/27 19:02
Boston Scientific Is the Worst Performing S&P 500 Stock. Here's Why.
TipRanks·05/23 02:07
Atricure Insider Move: High-Profile Director Cashes In on Recent Stock Holdings
PUBT·05/22 12:57
AtriCure director Karen Prange sells 3,000 shares for $85,950
TipRanks·05/19 21:23
AtriCure Shareholders Approve Expanded Equity and Governance Plans
TipRanks·05/19 02:17
Top Atricure Executive Makes Bold Insider Stock Move
TipRanks·05/07 05:47
AtriCure price target raised to $55 from $53 at Canaccord
TipRanks·05/07 02:19
AtriCure participates in a conference call with JPMorgan
TipRanks·05/07 00:25
AtriCure Earnings Call Highlights Profitable Growth Pivot
Dow Jones·05/06 23:08
AtriCure Is Maintained at Buy by Canaccord Genuity
Dow Jones·05/06 23:08
AtriCure Price Target Raised to $55.00/Share From $53.00 by Canaccord Genuity
Benzinga·05/06 22:58
Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $55
PUBT·05/06 17:50
AtriCure releases transcript of Q1 2026 earnings conference call
Same Industry
Name/Symbol
Change%
Price